27 results on '"Gennigens C"'
Search Results
2. Recurrent or primary metastatic cervical cancer: current and future treatments
3. CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.
4. Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe
5. Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion
6. 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study
7. 132MO Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study
8. 755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
9. Added value of para-aortic surgical staging compared to F-18-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study
10. 1720P How do oncological patients perceive the COVID-19 pandemic? Experience from CHU Liège in Belgium
11. LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
12. 1712P Risk of SARS-CoV-2 infection and outcome after infection: Experience from the day-care unit at CHU Liège in Belgium
13. A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort
14. A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
15. 963P - A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort
16. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
17. 931O - A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
18. Insulin-Like Growth Factor (IGF) family and prostate cancer
19. Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group
20. Diagnostic Performance of Immunohistochemistry Compared to Molecular Techniques for Microsatellite Instability and p53 Mutation Detection in Endometrial Cancer.
21. Bilateral breast desmoid-type fibromatosis, case report and literature review.
22. Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study.
23. Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy.
24. Treatment algorithm in patients with ovarian cancer.
25. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
26. Primary osteosarcoma of the breast: a case report.
27. Hodgkin's lymphoma presenting as a bladder tumour.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.